TARS Tarsus Pharmaceuticals Inc.

36.25
-1.31  -3%
Previous Close 37.56
Open 37.86
52 Week Low 15.3248
52 Week High 63.69
Market Cap $736,615,443
Shares 20,320,426
Float 11,666,024
Enterprise Value $651,101,442
Volume 24,826
Av. Daily Volume 102,614
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
TP-03 - Saturn-1
Demodex Blepharitis
Phase 2/3
Phase 2/3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced the appointment of Bryan Wahl, MD, JD to the position of General Counsel. Dr. Wahl brings over 15 years of broad legal experience, including significant intellectual property (IP), corporate, and transactional expertise, to the position. In this role, he will provide strategic direction as Tarsus expands its innovative product pipeline, beginning with TP-03 for the potential treatment of Demodex blepharitis.

    Most recently…

    IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced the appointment of Bryan Wahl, MD, JD to the position of General Counsel. Dr. Wahl brings over 15 years of broad legal experience, including significant intellectual property (IP), corporate, and transactional expertise, to the position. In this role, he will provide strategic direction as Tarsus expands its innovative product pipeline, beginning with TP-03 for the potential treatment of Demodex blepharitis.

    Most recently, Dr. Wahl was a Partner at Knobbe Martens LLP in Orange County, where he focused on intellectual property protection, infringement studies, and due diligence for financings and strategic transactions, specifically with respect to pharmaceutical, biotechnology, and medical device companies. In this role, Dr. Wahl counseled clients from the pre-Series A stage through exit, including Tarsus, which has been one of his clients since shortly after it was founded. Dr. Wahl has received numerous accolades and recognition for his work at the firm. In addition to his law practice, Dr. Wahl has practiced inpatient internal medicine since 2002, most recently as a per diem hospitalist with Kaiser Permanente, caring for patients both on hospital wards and in the ICU.

    "Since its founding, Tarsus has pursued meaningful innovation to address unmet patient needs," said Bobak Azamian, MD, PhD, CEO, Tarsus Pharmaceuticals, Inc. "As we continue to make our vision a reality, we are thrilled to welcome Bryan in the role of General Counsel. His unique combination of legal and medical expertise and breadth of corporate legal experience in strategic transactions and intellectual property will be invaluable to our leadership team as we discover and develop transformational new assets, both in eye care and other therapeutic areas."

    Prior to joining Knobbe Martens, Dr. Wahl entered medical school after one undergraduate year, and received his medical degree with honors from the University of Hawaii John A. Burns School of Medicine in 1999. He completed an internal medicine residency in the UCLA-affiliated Cedars-Sinai Medical Center program in Los Angeles in 2002, and is board certified in Internal Medicine. Dr. Wahl earned his law degree from the University of California, Berkeley School of Law in 2005. In law school, he received three American Jurisprudence Awards, two Prosser Awards, and the Barbee Fellowship, researching conflicts of interest of hospital institutional review boards, and was a summer extern for the Honorable Ronald T.Y. Moon, Chief Justice of the Hawaii Supreme Court.

    "It's an honor and a pleasure to join Tarsus as the company continues to evolve and advance its mission," said Dr. Wahl. "In this new role, I look forward to helping Tarsus develop truly innovative, important therapies, creating tangible value for patients, practitioners, and stakeholders."

    About Tarsus Pharmaceuticals, Inc.

    Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

    Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding future events and Tarsus' plans for and the anticipated benefits of its product candidates, the timing, objectives and results of the clinical studies and anticipated regulatory and development milestones. The words, without limitation, "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, and are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Media Contact:

    Allison Howell

    Pascale Communications, LLC

    Investor Contact:

    Patti Bank

    Westwicke Partners, an ICR company

    (415) 513-1284

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/280c8aad-5a23-4670-be0b-9c3585d3d383



    Primary Logo

    View Full Article Hide Full Article
  2. IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced the appointment of Dianne Whitfield to the position of Chief Human Resources (HR) Officer. Ms. Whitfield has more than 20 years of experience in human resources, including over a decade of management and leadership experiences in the life sciences industry.

    Most recently, Ms. Whitfield served as Vice President and Head of Human Resources for Evolus, Inc., where she led efforts to support the commercialization of the startup…

    IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced the appointment of Dianne Whitfield to the position of Chief Human Resources (HR) Officer. Ms. Whitfield has more than 20 years of experience in human resources, including over a decade of management and leadership experiences in the life sciences industry.

    Most recently, Ms. Whitfield served as Vice President and Head of Human Resources for Evolus, Inc., where she led efforts to support the commercialization of the startup company's first approved product. While at Evolus, she designed strategy and executed programs focused on recruiting top talent and building a positive culture and an effective employee experience, to drive engagement and business results.

    "Dianne's appointment to the position of Chief HR Officer comes at an incredibly exciting time for our business, as we lay the foundation for long-term organizational growth," said Bobak Azamian, MD, PhD, CEO, Tarsus Pharmaceuticals, Inc. "Dianne brings a wealth of leadership experience, including her recent tenure at Evolus, where she built a talented, multifunctional team in a growing startup, defined an engaging culture, and supported the launch of a new pharmaceutical product. We look forward to Dianne's leadership as we continue to build the Tarsus team and a culture that will best enable our company's mission."

    Prior to Evolus, Ms. Whitfield held positions of increasing responsibility at Allergan (an AbbVie company) where she progressed to the role of Director of Global Human Resources. Her experience there spanned a variety of human resources business partnership and leadership roles where she supported both the Commercial and Research & Development organizations and led enterprise-wide initiatives in Global Talent Management. She has broad experience building organizations and supporting product launches in multiple therapeutic areas including eye care, as well as expertise in developing culture and talent programs to drive organizational success. Dianne holds a Bachelor of Arts in Psychology and Social Behavior from the University of California, Irvine and a Masters in Social Work from California State University, Long Beach.

    "I'm thrilled to join the experienced and talented management team at Tarsus, and look forward to driving its next phase of growth by curating a differentiated culture that captures the Tarsus spirit of innovation, and enables talent to achieve our mission," said Ms. Whitfield.

    About Tarsus Pharmaceuticals, Inc.

    Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

    Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding future events and Tarsus' plans for and the anticipated benefits of its product candidates, the timing, objectives and results of the clinical studies and anticipated regulatory and development milestones. The words, without limitation, "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, and are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Media Contact:

    Allison Howell

    Pascale Communications, LLC

    Investor Contact:

    Patti Bank

    Westwicke Partners, an ICR company

    (415) 513-1284

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5be39cb4-2eac-49dc-9d36-4eedaaca35c9



    Primary Logo

    View Full Article Hide Full Article
  3. IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced Bobak Azamian, M.D., Ph.D., CEO of Tarsus, will present an overview of the company at the ICR Conference 2021, being held virtually from January 11-14. In addition to the presentation, the management team will host investor meetings at the conference.

    Presentation Details
    Date: Thursday, January 14
    Time: 2:30 PM ET/ 11:30 AM PT
    Webcast: https://icrinc.touchcast.com/showtime/icr-conference/embed/bfed7351-70cc-6af4-2d71-56748a5bcfa7

    IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced Bobak Azamian, M.D., Ph.D., CEO of Tarsus, will present an overview of the company at the ICR Conference 2021, being held virtually from January 11-14. In addition to the presentation, the management team will host investor meetings at the conference.

    Presentation Details

    Date: Thursday, January 14

    Time: 2:30 PM ET/ 11:30 AM PT

    Webcast: https://icrinc.touchcast.com/showtime/icr-conference/embed/bfed7351-70cc-6af4-2d71-56748a5bcfa7

    The live webcast will be hosted on ir.tarsusrx.com and available for replay for a period of 90 days.

    About Tarsus Pharmaceuticals, Inc.

    Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

    Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, and are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Investor Contact:

    Patti Bank

    Westwicke Partners, an ICR company

    (415) 513-1284

    Media Contact:

    Allison Howell

    Pascale Communications, LLC



    Primary Logo

    View Full Article Hide Full Article
  4. IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced that it received written minutes from the (Type C) meeting held on December 8 with the United States Food and Drug Administration (FDA). The meeting was held to align on specific NDA submission requirements for TP-03, a novel therapeutic in development for the treatment of Demodex blepharitis, and the Company believes it received collaborative and productive guidance.

    "Recently, we held a productive Type C meeting with the…

    IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced that it received written minutes from the (Type C) meeting held on December 8 with the United States Food and Drug Administration (FDA). The meeting was held to align on specific NDA submission requirements for TP-03, a novel therapeutic in development for the treatment of Demodex blepharitis, and the Company believes it received collaborative and productive guidance.

    "Recently, we held a productive Type C meeting with the FDA. At this meeting, we obtained valuable feedback on the data requirements for an NDA filing consistent with our existing plans: specifically, regarding the non-clinical toxicology, clinical and CMC components," said Sesha Neervannan, COO of Tarsus. "We are pleased to continue advancing TP-03 through its pivotal trials and towards a potential NDA filing in order to provide the more than 9 million people in the United States that suffer from Demodex blepharitis a potential therapeutic treatment option."

    Recently, Tarsus completed its Io and Europa Phase 2 clinical trials, and began enrolling patients in Saturn-1, its Phase 2b/3 pivotal trial. The company plans to initiate its second pivotal registration trial, Saturn-2, in 2021, and expects for the data to support the potential submission of an NDA for TP-03 to treat Demodex blepharitis. TP-03 has the potential to be the first FDA-approved therapeutic and standard of care for the treatment of Demodex blepharitis.

    About TP-03

    TP-03 (lotilaner ophthalmic solution 0.25%) is a novel therapeutic designed to target and eradicate Demodex mites. It is a potent, non-competitive antagonist of insect and arachnid GABA-Cl channels and a highly lipophilic molecule, which may promote its uptake in the oily sebum of the hair follicle where the mites reside. TP-03 has completed four Phase 2 clinical trials in Demodex blepharitis, all of which met their respective endpoints. It was well-tolerated with no significant adverse events nor any events leading to treatment discontinuation across the four trials. TP-03 is currently being evaluated in the Saturn-1 pivotal Phase 2b/3 trial and may offer treatment, if approved, for millions of patients with Demodex blepharitis.  

    About Demodex Blepharitis

    Blepharitis is a common ocular condition that is characterized by inflammation of the eyelid margin, redness and ocular irritation. Demodex blepharitis is caused by infestation of Demodex mites, the most common ectoparasite found on humans. Demodex mites cause approximately 45%, or about 9 million, of blepharitis cases in the US and the number may be as high as approximately 25 million based on Tarsus' internal research indicating about 58% of patients presenting to eye care clinics have collarettes, a pathognomonic sign of Demodex infestation, and a published study estimating that at least 45 million people annually visit an eye care clinic. Currently, there are no FDA-approved treatments for Demodex blepharitis.

    About Tarsus Pharmaceuticals, Inc.

    Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

    Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding future events and Tarsus' plans for and the anticipated benefits of its product candidates, the timing, objectives and results of the clinical studies and anticipated regulatory and development milestones. The words, without limitation, "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, and are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Media Contact:

    Allison Howell

    Pascale Communications, LLC

    Investor Contact:

    Patti Bank

    Westwicke Partners, an ICR company

    (415) 513-1284



    Primary Logo

    View Full Article Hide Full Article
  5. IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced that it has been added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index as part of the index's quarterly initial public offering (IPO) additions.

    Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell…

    IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced that it has been added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index as part of the index's quarterly initial public offering (IPO) additions.

    Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

    Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

    For more information on the Russell Indexes, please visit the "Russell Reconstitution" section on the FTSE Russell website at www.ftserussell.com.

    About Tarsus Pharmaceuticals, Inc.

    Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

    Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, and are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Investor Contact:

    Patti Bank

    Westwicke Partners, an ICR company

    (415) 513-1284

    Media Contact:

    Allison Howell

    Pascale Communications, LLC



    Primary Logo

    View Full Article Hide Full Article
View All Tarsus Pharmaceuticals Inc. News